Miller School of Medicine, University of Miami, Miami, Florida, USA.
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Cancer Med. 2024 Nov;13(21):e70384. doi: 10.1002/cam4.70384.
This study aims to describe patterns, sources, and reasons for cannabis use among cancer patients during active treatment (+CDTX) compared to no-use during active treatment (-CDTX).
Data are from 385 surveys collected via REDCap during phase I of an ongoing study among adult cancer patients seen at an NCI-designated comprehensive cancer center within the last 5 years of treatment. A harmonized survey was created with 11 other NCI centers to assess cannabis use patterns, sources, and reasons for use. Sociodemographics and cancer details were also collected via self-report. Descriptive statistics were calculated and stratified by +/-CDTX. Chi-squared tests were conducted to compare proportions between groups.
Among the sample [49.5 years (SD 15.9); 53.0% male; and 41.6% Hispanic/Latino], 41.0% + CDTX and 59.0% -CDTX. A majority (71.8%) of +CDTX initiated use before diagnosis versus 44.1% in -CDTX (p < 0.0001); patients diagnosed with stage 4 cancer had a statistically significant higher prevalence of +CDTX (60.0%; p = 0.003); 53.3% in radiation reported +CDTX compared to 42.8% in chemotherapy, and 36.4% in immunotherapy. Dispensaries and local dealers were the top sources of cannabis in both groups. Among +CDTX, 44.3% consumed cannabis at least once a day DTX, dominant cannabinoids used were CBD (35.2%), Delta-8-THC (18.3%), and CBD + THC ratio (14.1%); 12.7% were unsure what they consumed. Joints were the most common inhalation method (61.5%), and store-bought candy was the most common edible (39.2%). Depression/mood, pain, and enjoyment were the top three reasons for +CDTX compared to enjoyment, depression/mood, and nausea/upset stomach in -CDTX (p = 0.02).
Patterns, sources, and reasons for cannabis use varied between +CDTX and -CDTX. Future studies should examine the impacts of cannabis and specific cannabinoids on cancer treatment, drug interactions, survival outcomes, and quality of life.
本研究旨在描述癌症患者在积极治疗期间（+CDTX）与不使用期间（-CDTX）使用大麻的模式、来源和原因。
数据来自于 385 份通过 REDCap 在一个正在进行的研究的第一阶段收集的调查，该研究对象为过去 5 年内接受 NCI 指定的综合性癌症中心治疗的成年癌症患者。创建了一个与其他 11 个 NCI 中心协调一致的调查，以评估大麻使用模式、来源和使用原因。还通过自我报告收集了社会人口统计学和癌症细节。计算了描述性统计数据，并按 +/-CDTX 进行了分层。使用卡方检验比较了组间的比例。
在样本中（[49.5 岁（SD 15.9）]；53.0%男性；41.6%西班牙裔/拉丁裔），41.0%+CDTX 和 59.0%-CDTX。大多数（71.8%）+CDTX 在诊断前开始使用，而 -CDTX 为 44.1%（p<0.0001）；诊断为 4 期癌症的患者+CDTX 的患病率具有统计学意义更高（60.0%；p=0.003）；接受放疗的患者中有 53.3%报告了+CDTX，而接受化疗的患者为 42.8%，接受免疫治疗的患者为 36.4%。药房和当地经销商是两组中大麻的主要来源。在+CDTX 中，44.3%的患者每天至少使用一次 DTX 大麻，使用的主要大麻素为 CBD（35.2%）、Delta-8-THC（18.3%）和 CBD+THC 比值（14.1%）；12.7%的人不确定自己使用的是什么。关节是最常见的吸入方式（61.5%），商店购买的糖果是最常见的可食用形式（39.2%）。与 -CDTX 相比，抑郁/情绪、疼痛和享受是+CDTX 的前三大原因，而在 -CDTX 中，享受、抑郁/情绪和恶心/胃部不适是前三大原因（p=0.02）。
+CDTX 和 -CDTX 之间的大麻使用模式、来源和原因存在差异。未来的研究应探讨大麻和特定大麻素对癌症治疗、药物相互作用、生存结果和生活质量的影响。
